SEC Insider Transactions from Mandel-Brehm Josh.

Last updated: 2026-04-03 21:06 UTC | Total transactions: 8

Josh Mandel-Brehm, CEO of Camp4 Therapeutics Corp ($CAMP), made one open market purchase of shares in the last year, totaling $10,000. His most recent buy occurred on September 11, 2025. This places him 4308th out of 4983 insiders by purchase value, well below the average of $1.5 million across 3.29 transactions per buyer. He reported no open market sales.

Set Up your own filters →
Transaction Date Company Ticker Insider Name Title Transaction Type Security Shares Price Shares Owned Following Total Shares Outstanding % of Owned % of Outstanding
April 1, 2026 Camp4 Therapeutics Corp $CAMP Mandel-Brehm Josh Chief Executive Officer A Stock Option (Right to Buy) 580000 $0.00 580,000.0000 46,881,134 9999.99% 1.24%
Dec. 11, 2025 Camp4 Therapeutics Corp $CAMP Mandel-Brehm Josh Chief Executive Officer A Stock Option (Right to Buy) 425000 $0.00 425,000.0000 46,881,134 9999.99% 0.91%
Sept. 11, 2025 Camp4 Therapeutics Corp $CAMP Mandel-Brehm Josh Chief Executive Officer P Common Stock 6060 $1.65 278,417.0000 20,161,072 2.23% 0.03%
June 12, 2025 ProMIS Neurosciences Inc. $PMN Mandel-Brehm Josh Director A Option (right to buy) 20000 $0.00 20,000.0000 34,851,203 9999.99% 0.06%
April 1, 2025 Camp4 Therapeutics Corp $CAMP Mandel-Brehm Josh Chief Executive Officer A Stock Option (Right to Buy) 160000 $0.00 160,000.0000 20,161,072 9999.99% 0.79%
Oct. 15, 2024 Camp4 Therapeutics Corp $CAMP Mandel-Brehm Josh Chief Executive Officer C Series B Preferred Stock 6791 $0.00 0.0000 0 100.00% 0.00%
Oct. 15, 2024 Camp4 Therapeutics Corp $CAMP Mandel-Brehm Josh Chief Executive Officer C Common Stock 605 $0.00 272,357.0000 0 0.22% 0.00%
Oct. 3, 2024 ProMIS Neurosciences Inc. $PMN Mandel-Brehm Josh Director A Option (right to buy) 40000 $0.00 40,000.0000 30,067,095 9999.99% 0.13%